Formulary
Emtricitabine with rilpivirine and tenofovir alafenamide: Indications, Dosing, Side Effects and Interactions
Emtricitabine with rilpivirine and tenofovir alafenamide clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Emtricitabine with rilpivirine and tenofovir alafenamide: Indications, Dosing, Side Effects and Interactions
Emtricitabine with rilpivirine and tenofovir alafenamide clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**HIV infection in patients with plasma HIV-1 RNA concentration of 100 000 copies/mL or less (specialist use only)**
- **Adult** (By Mouth): 1 tablet once daily.
**HIV infection in patients with plasma HIV-1 RNA concentration of 100 000 copies/mL or less (specialist use only) for emtricitabine with rilpivirine and tenofovir alafenamide**
- **Child 12-17 years (body-weight 35 kg and above)** (By mouth): 1 tablet once daily.
Side effects
For emtricitabine with rilpivirine and tenofovir alafenamide Common or very common Appetite decreased; depression; diarrhoea; dizziness; drowsiness; dry mouth; fatigue; flatulence; gastrointestinal discomfort; headache; nausea; skin reactions; sleep disorders; vomiting Uncommon Anaemia; angioedema; arthralgia; immune reconstitution inflammatory syndrome; severe cutaneous adverse reactions (SCARs) Frequency not known Conjunctivitis; eosinophilia; fever; osteonecrosis Side-effects, further information Systemic symptoms reported with severe skin reactions include fever, blisters, conjunctivitis, angioedema, elevated liver function tests, and eosinophilia.
Hepatic impairment
For emtricitabine with rilpivirine and tenofovir alafenamide Manufacturer advises caution in moderate impairment (increased risk of hepatic side-effects); avoid in severe impairment (no information available).
Renal impairment
For emtricitabine with rilpivirine and tenofovir alafenamide Manufacturer advises avoid if creatinine clearance less than 30 mL/minute-no information available. See Prescribing in renal impairment .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Emtricitabine with rilpivirine and tenofovir alafenamide in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

